Pharmaceutics, 2022 To assess anatomical and functional outcomes after switching from dexamethasone implant (DEXi) to fluocinolone acetonide implant (FAci) in 113 diabetic macular edema eyes, a multicentric retrospective observational study was conducted. Seventy-five eyes (
Stephanie Baillif +2 more
exaly +6 more sources
Fluocinolone intravitreal implant (Iluvien) for macular edema secondary to immune recovery uveitis in patient with acute myeloid leukemia [PDF]
Journal of Ophthalmic Inflammation and InfectionPurpose To report the use of Fluocinolone intravitreal implant (Iluvien) for the treatment of persistent cystoid macular edema (CME) due to immune recovery uveitis syndrome in a patient with previous cytomegalovirus retinitis and acute myeloid leukemia ...
JM Cachero Rodríguez +3 more
doaj +2 more sources
Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience [PDF]
Scientific Reports, 2021 We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME ...
Matteo Fallico +14 more
doaj +2 more sources
Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries [PDF]
Ophthalmology and Therapy, 2022 Introduction: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO).
Louis Arnould +2 more
exaly +5 more sources
Prevalence and Risk Factors of Ocular Hypertension Following Fluocinolone Acetonide (Iluvien®) Intravitreal Injections: The “SAFAC” Study [PDF]
Ophthalmology and TherapyIntroduction The aim of this real-life study was to analyze the prevalence and risk factors of ocular hypertension (OHT) after fluocinolone acetonide implant (FAc-I) intravitreal injections in the treatment of macular edema of various etiologies. Methods
Yasmine Serrar +9 more
doaj +2 more sources
Long-term outcomes of intravitreal 0.19 mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments [PDF]
Journal of Ophthalmic Inflammation and InfectionBackground This study evaluates the long-term efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide implant (FAi) in non-infectious UME, comparing it with prior sub-Tenon’s triamcinolone acetonide (STTA) and/or intravitreal dexamethasone ...
Ana Margarida Ferreira +6 more
doaj +2 more sources
Clinical Ophthalmology, 2021 Laura R Steeples,1,2 Sasa Pockar,1 Nicholas P Jones,1,2 Inês Leal3,4 1Manchester Royal Eye Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; 2Faculty of Biology, Medicine &
Ines Leal
exaly +2 more sources
Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study [PDF]
Journal of Ophthalmic Inflammation and InfectionBackground Postoperative cystoid macular edema (PCME) is a primary cause of reduced vision following both cataract and/or vitreoretinal surgery, which may spontaneously resolve.
Maria Madeira +4 more
doaj +2 more sources
Efficacy and Safety of Fluocinolone Acetonide Implant in Diabetic Macular Edema: Practical Guidelines from Reference Center [PDF]
PharmaceuticsDiabetic macular edema (DME) is a common complication of diabetic retinopathy. Treatment with intravitreal injections is effective in most cases but is associated with a high therapeutic burden for patients. This implies the need for long-term treatments,
Lucas Sejournet +6 more
doaj +2 more sources
Case Reports in Ophthalmology, 2021 Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is a rare and progressive disorder that predominantly affects both the eyes of young female individuals and can threaten visual function.
Lucía Moreno-Castro +3 more
doaj +1 more source